Cellectis - Asset Resilience Ratio

Latest as of June 2026: 49.09%

Cellectis (ALCLS) has an Asset Resilience Ratio of 49.09% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALCLS net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€131.26 Million

≈ $153.45 Million USD Cash + Short-term Investments

Total Assets

€267.37 Million

≈ $312.58 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2006–2025)

This chart shows how Cellectis's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Cellectis's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down Cellectis's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ALCLS long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€131.26 Million	49.09%
Total Liquid Assets	€131.26 Million	49.09%

Asset Resilience Insights

Very High Liquidity: Cellectis maintains exceptional liquid asset reserves at 49.09% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Cellectis Industry Peers by Asset Resilience Ratio

Compare Cellectis's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
Genscript Biotech Corporation F:G51	Biotechnology	13.79%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
89bio Inc NASDAQ:ETNB	Biotechnology	71.60%
Pacific Shuanglin Bio pharmacy Co Ltd SHE:000403	Biotechnology	2.66%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	74.48%

Annual Asset Resilience Ratio for Cellectis (2006–2025)

The table below shows the annual Asset Resilience Ratio data for Cellectis.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	50.12%	€162.75 Million ≈ $190.27 Million	€324.72 Million ≈ $379.63 Million	-9.17pp
2024-12-31	59.29%	€227.39 Million ≈ $265.84 Million	€383.54 Million ≈ $448.40 Million	+22.76pp
2023-12-31	36.53%	€122.11 Million ≈ $142.76 Million	€334.27 Million ≈ $390.80 Million	+29.22pp
2022-12-31	7.31%	€19.11 Million ≈ $22.34 Million	€261.22 Million ≈ $305.39 Million	-5.36pp
2021-12-31	12.67%	€48.41 Million ≈ $56.60 Million	€382.08 Million ≈ $446.69 Million	-9.41pp
2020-12-31	22.08%	€103.65 Million ≈ $121.18 Million	€469.47 Million ≈ $548.86 Million	+2.77pp
2019-12-31	19.31%	€90.28 Million ≈ $105.54 Million	€467.47 Million ≈ $546.52 Million	+8.59pp
2018-12-31	10.72%	€53.71 Million ≈ $62.79 Million	€500.84 Million ≈ $585.53 Million	-21.20pp
2016-12-31	31.93%	€105.58 Million ≈ $123.43 Million	€330.68 Million ≈ $386.60 Million	+9.94pp
2007-12-31	21.99%	€11.85 Million ≈ $13.85 Million	€53.87 Million ≈ $62.98 Million	+19.41pp
2006-12-31	2.58%	€287.00K ≈ $335.53K	€11.13 Million ≈ $13.01 Million	--

pp = percentage points

About Cellectis

PA:ALCLS France Biotechnology

Market Cap

$111.46 Million

€95.33 Million EUR

Market Cap Rank

#18897 Global

#273 in France

Share Price

€1.31

Change (1 day)

+7.28%

52-Week Range

€1.15 - €4.57

All Time High

€40.90